Celularity Selects Cryoport’s Temperature Controlled Logistics Solutions

Cryoport, Inc. announced it has been selected by Celularity to utilize its complete range of temperature-controlled solutions.

Cryoport is the life sciences industry’s foremost temperature-controlled logistics provider, supporting over 357 clinical trials globally as well as blockbuster FDA-approved CAR-T therapies from Novartis and Gilead.

Celularity is a clinical-stage cell therapeutics company developing allogeneic cellular therapies harnessed from human placentas through its proprietary IMPACT platform across immuno-oncology, inflammatory & age-related diseases. The agreement will give Celularity access to Cryoport’s full suite of temperature-controlled logistics solutions, including the Cryoport Express shippers, the industry-leading Cryoportal Logistics Management Platform, Smartpak II™ Condition Monitoring System and 24/7/365 logistics support.

Jerrell Shelton, Chief Executive Officer of Cryoport, said, “We are proud to support Celularity’s clinical programs for the development of transformative allogeneic cell therapies. Cryoport’s end-to-end, industry-leading, temperature-controlled logistics solutions protect the biologic commodities that underpin these potentially ground-breaking therapies and play a vital role in their development.”

John R. Haines, Chief Administrative Officer of Celularity, said, “Celularity’s IMPACT platform seamlessly integrates biosourcing through advanced cell manufacturing and productization of allogeneic placental-derived cell therapeutics. Industry-leading supply chain management tools are critical to our ability to deliver transformative, on-demand, off-the-shelf therapeutic options to patients in the United States and worldwide. We look forward to partnering with Cryoport for cell therapy product logistics management.”